-
Was your treatment approved?
Did you read on the ALS News Today website that “Clene Nanomedicine has nearly doubled the enrollment cap for a soon-to-launch expanded access program (EAP) to allow more patients to receive CNM-Au8 — its investigational treatment for amyotrophic lateral sclerosis (ALS) — outside of clinical trials”?
When I attempted to get on Tofersen the EAP, it didn’t go through. It appeared to be a problem between the pharma company and the university where it would be administered. It was initially requested in early December 2022. In April, all requests were put on hold. Then the FDA conditionally approved it. I didn’t start until July 12th.
Have you applied for any treatments through the EAP? If so, what was the process like for you and were you approved?
https://alsnewstoday.com/news/cnm-au8-expanded-access-program-will-enroll-more-als-patients/
clene.com
Clene Inc. | Nanomedicine in Pharmaceutical Research
Clene Inc. | Nanomedicine in Pharmaceutical Research
-
1 Reply
-
Clene has an EPA Extensión Protocol Access. I emailed direct to Clene and they answered me there are 2 ways to Access: 1. Healey Platform C 2. Contact synapticure.
Log in to reply.